Anika Therapeutics Q1 2024 Adj EPS $0.09 Beats $(0.19) Estimate, Sales $40.523M Beat $39.143M Estimate
Anika Therapeutics Q1 2024 Adj EPS $0.09 Beats $(0.19) Estimate, Sales $40.523M Beat $39.143M Estimate
Anika Therapeutics 2024年第一季度調整後每股收益爲0.09美元，超過預期（0.19美元），銷售額爲4,0523萬美元超過3,914.43萬美元的預期
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.19) by 147.37 percent. The company reported quarterly sales of $40.523 million which beat the analyst consensus estimate of $39.143 million by 3.53 percent. This is a 6.85 percent increase over sales of $37.924 million the same period last year.
Anika Therapeutics（納斯達克股票代碼：ANIK）公佈的季度收益爲每股0.09美元，比分析師共識估計的美元（0.19美元）高出147.37％。該公司公佈的季度銷售額爲4,0523萬美元，比分析師普遍預期的3914.3萬美元高出3.53％。這比去年同期的3792.4萬美元的銷售額增長了6.85％。